Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

被引：18

作者：

Abou-Alfa, Ghassan K.

Mollon, Patrick

Meyer, Tim

Cheng, Ann-Lii

El-Khoueiry, Anthony B.

Kelley, Robin Kate

Baron, Ari David

Benzaghou, Fawzi

Valcheva, Velichka Valerieva

Hazra, Saswati

Mangeshkar, Milan

Freemantle, Nicholas

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] IPSEN, Abingdon, Oxon, England

[3] UCL, Canc Inst, London, England

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[8] Pacific Hem Onc Assoc, Mill Valley, CA USA

[9] IPSEN, Paris, France

[10] Ipsen Pharma SAS, Paris, France

[11] Prometheus Lab Inc, San Diego, CA USA

[12] Exelixis Inc, San Francisco, CA USA

[13] UCL, London, England

来源：

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.207

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

207

引用

页数：2